display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvantbreast cancer - HR positive
breast cancer - adjuvantla/mBC - HR-positive - 2nd line (L2)
mTOR inhibitors
everolimus Bachelot
sapanisertib plus fulvestrant NCT02756364 ... NCT02756364 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons